The FDA approved Medtronic’s defibrillator that tailors cardiac resynchronization therapy (CRT) to each patient by using an algorithm to adjust pacing. With its ability to confirm if pulses are ...

North Shore University Hospital’s cardiology team became the first to complete a procedure using the novel OmniaSecure ...

BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

Criteria to identify appropriate candidates for CRT and CRT-D are based on the experiences gained during clinical trials ( Table II). Trials to date have predominantly included patients with normal ...

AtaCor, a cardiac rhythm management (CRM) company, develops extravascular defibrillation technologies. Its offerings aim to ...

NEW ORLEANS -- An investigational extravascular implantable cardioverter-defibrillator (ICD) continues to demonstrate it can appropriately shock patients and prevent sudden cardiac death, extended ...

NICE, FRANCE — Preliminary data suggest cardiac pacing is feasible with implantable cardioverter-defibrillator (ICD) leads placed outside the heart and under the rib cage [1]. Leads were temporarily ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study.

Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...